Search

Displaying results 7241 - 7250 of 10000 in total
  1. Drug

    Enrofloxacin

    go.drugbank.com/drugs/DB11404
    InvestigationalVet approved

    Due to the identification of fluoroquinolone-resistant strains of _Campylobacter_, in September 2005, the FDA withdrew the approval of enrofloxacin for its use in water to treat flocks of poultry. … Enrofloxacin is an antibiotic agent from the fluoroquinolone family produced by the Bayer Corporation. Enrofloxacin is approved by the FDA for its veterinary use.

  2. Drug

    CGC-11047

    go.drugbank.com/drugs/DB05722
    Investigational

    CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.

  3. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.

  4. Drug

    OSI-461

    go.drugbank.com/drugs/DB05415
    Investigational

    OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).

  5. Drug

    Taribavirin

    go.drugbank.com/drugs/DB06408
    Investigational

  6. Drug

    IN01

    go.drugbank.com/drugs/DB16434
    Experimental

    Of note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130). … The study will explore the effect of this vaccine on pulmonary function, oxygen saturation, quality of life, and fibrosing status in addition to biomarkers and molecular markers of the vaccine.

  7. Drug

    NCX 701

    go.drugbank.com/drugs/DB05409
    Experimental

    Nitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.

  8. Drug

    177Lu-NI-FAPI

    go.drugbank.com/drugs/DB33977
    Experimental

    177Lu-NI-FAPI is a small molecule drug. 177Lu-NI-FAPI is under investigation in clinical trial NCT07822347 (Research on NI-FAPI-04 for the Treatment of Hypoxic and Fibroblast Activation Protein Related

  9. Drug

    AVR-RD-04

    go.drugbank.com/drugs/DB18644
    Experimental

    AVR-RD-04 is an investigational gene therapy for cystinosis. … It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin.

    Synonyms: autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin
  10. Drug

    TST10088

    go.drugbank.com/drugs/DB05151
    Experimental

    TST10088 has been designed and engineered by Twinstrand to contain a peptide switch that is specifically cleaved by the matrix metalloproteinases which are known to be involved in tumor growth and metastasis